Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- IRCCS Policlinico S. Donato
- Target Recruit Count
- 1140
- Registration Number
- NCT05566301
- Locations
- 🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
- Conditions
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Universiti Sains Malaysia
- Target Recruit Count
- 80
- Registration Number
- NCT05516784
- Locations
- 🇲🇾
Department of Cardiology, Penang General Hospital, George Town, Penang, Malaysia
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of L'Aquila
- Target Recruit Count
- 2239
- Registration Number
- NCT05476081
- Locations
- 🇮🇹
Neurology e Stroke Unit Departement, SS Filippo e Nicola Hospital, Avezzano, Abruzzo, Italy
🇮🇹Department of Neurology and Stroke Unit, Ente Ecclesiastico ospedale Generale Regionale Miulli, Acquaviva Delle Fonti, Italy
🇮🇹Department of Neurology, Murgia Hospital Fabio Perinei SS 96, Altamura, Italy
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05373277
- Locations
- 🇫🇮
Department of Clinical Pharmacology, Helsinki, Finland
GM03 - Platelet RNA Signatures of Aspirin
- Conditions
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 135
- Registration Number
- NCT05278637
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 87
- Registration Number
- NCT05247385
- Locations
- 🇧🇷
Heart Institute (InCor) / University of São Paulo, São Paulo, Sao Paulo, Brazil
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05209412
- Locations
- 🇨🇳
Ling Tao, Xi'an, Shannxi, China
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 204
- Registration Number
- NCT05166538
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 30
- Registration Number
- NCT05116995
- Locations
- 🇨🇦
Nova Scotia Health, Halifax, Nova Scotia, Canada
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT05093790
- Locations
- 🇬🇧
Local Institution - 0001, Edinburgh, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.